287 related articles for article (PubMed ID: 26317903)
21. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
[TBL] [Abstract][Full Text] [Related]
22. The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies.
Malaney P; Velasco-Estevez M; Aguilar-Garrido P; Aitken MJL; Chan LE; Zhang X; Post SM; Gallardo M
Front Immunol; 2021; 12():634584. PubMed ID: 33912162
[TBL] [Abstract][Full Text] [Related]
23. Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/β-catenin pathway to promote growth and metastasis in colorectal cancer.
Zhang Z; Zhou C; Chang Y; Zhang Z; Hu Y; Zhang F; Lu Y; Zheng L; Zhang W; Li X; Li X
Cancer Lett; 2016 Jun; 376(1):62-73. PubMed ID: 27012187
[TBL] [Abstract][Full Text] [Related]
24. Anticancer activities of curcumin on human Burkitt's lymphoma.
Wu Y; Chen Y; Xu J; Lu L
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):348-52. PubMed ID: 12408761
[TBL] [Abstract][Full Text] [Related]
25. c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.
Scheller H; Tobollik S; Kutzera A; Eder M; Unterlehberg J; Pfeil I; Jungnickel B
Oncogene; 2010 Feb; 29(6):888-97. PubMed ID: 19881537
[TBL] [Abstract][Full Text] [Related]
26. The localization of hnRNP A2/B1 in nuclear matrix and the aberrant expression during the RA-induced differentiation of human neuroblastoma SK-N-SH cells.
Liang Y; Shi SL; Li QF; Chen LY; Jing GJ; Tan GW; Wang SY; Wu FY
J Cell Biochem; 2011 Jul; 112(7):1722-9. PubMed ID: 21321999
[TBL] [Abstract][Full Text] [Related]
27. Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells.
Kobayashi M; Nakamura S; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Ohnishi K
Eur J Haematol; 2005 Sep; 75(3):212-20. PubMed ID: 16104877
[TBL] [Abstract][Full Text] [Related]
28. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.
Scholtysik R; Kreuz M; Klapper W; Burkhardt B; Feller AC; Hummel M; Loeffler M; Rosolowski M; Schwaenen C; Spang R; Stein H; Thorns C; Trümper L; Vater I; Wessendorf S; Zenz T; Siebert R; Küppers R;
Haematologica; 2010 Dec; 95(12):2047-55. PubMed ID: 20823134
[TBL] [Abstract][Full Text] [Related]
29. β-elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway.
Hu T; Gao Y
Biomed Pharmacother; 2018 Oct; 106():1557-1562. PubMed ID: 30119230
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
31. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
32. Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis.
Kaptein JS; Lin CK; Wang CL; Nguyen TT; Kalunta CI; Park E; Chen FS; Lad PM
J Biol Chem; 1996 Aug; 271(31):18875-84. PubMed ID: 8702548
[TBL] [Abstract][Full Text] [Related]
33. Characterization of multiple alternative forms of heterogeneous nuclear ribonucleoprotein K by phosphate-affinity electrophoresis.
Kimura Y; Nagata K; Suzuki N; Yokoyama R; Yamanaka Y; Kitamura H; Hirano H; Ohara O
Proteomics; 2010 Nov; 10(21):3884-95. PubMed ID: 20960454
[TBL] [Abstract][Full Text] [Related]
34. Role and mechanism of PTEN in Burkitt's lymphoma.
Li C; Xu Y; Xin P; Zheng Y; Zhu X
Oncol Rep; 2020 Feb; 43(2):481-490. PubMed ID: 31922234
[TBL] [Abstract][Full Text] [Related]
35. hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors.
Xiao Z; Ko HL; Goh EH; Wang B; Ren EC
Carcinogenesis; 2013 Jul; 34(7):1458-67. PubMed ID: 23455382
[TBL] [Abstract][Full Text] [Related]
36. Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.
Gao XZ; Zhao WG; Wang GN; Cui MY; Zhang YR; Li WC
Mol Med Rep; 2016 Feb; 13(2):1269-74. PubMed ID: 26648013
[TBL] [Abstract][Full Text] [Related]
37. Molecular biology of Burkitt's lymphoma.
Hecht JL; Aster JC
J Clin Oncol; 2000 Nov; 18(21):3707-21. PubMed ID: 11054444
[TBL] [Abstract][Full Text] [Related]
38. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.
Boffa LC; Cutrona G; Cilli M; Mariani MR; Matis S; Pastorino M; Damonte G; Millo E; Roncella S; Ferrarini M
Oligonucleotides; 2005; 15(2):85-93. PubMed ID: 15989423
[TBL] [Abstract][Full Text] [Related]
39. Increased level of Oct-1 protein in tumor cells modulates cellular response to anticancer drugs.
Portseva TN; Pankratova EV; Stepchenko AG; Georgieva SG
Dokl Biochem Biophys; 2016 Jul; 469(1):269-72. PubMed ID: 27599509
[TBL] [Abstract][Full Text] [Related]
40. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
